Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis

S Mannweiler, P Amersdorfer, S Trajanoski… - Pathology & Oncology …, 2009 - Springer
S Mannweiler, P Amersdorfer, S Trajanoski, JA Terrett, D King, G Mehes
Pathology & Oncology Research, 2009Springer
Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is
overexpressed in advanced stage prostate adenocarcinomas. As a novel target for in vivo
prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and
metastatic tumors is of significant interest. In this study we addressed the cellular distribution
and heterogeneity of PSMA expression. Paraffin-embedded sections of 51 patients with
primary prostate carcinoma and distant metastases were evaluated. Immunohistochemistry …
Abstract
Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas. As a novel target for in vivo prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and metastatic tumors is of significant interest. In this study we addressed the cellular distribution and heterogeneity of PSMA expression. Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated. Immunohistochemistry was used to determine the cellular localization, staining intensity and positive cell fraction which were related to tumor type and growth pattern. We demonstrated differences in the intracellular localization of the PSMA immunostaining which seem to be related to the tumor differentiation pattern. A significant number of the primary tumors (7/51) and metastases (6/51) presented with highly heterogeneous PSMA expression and in further 2 primary, and 8 metastatic tumors the staining was in the negative range (<10% positive tumor cells). A direct correlation between histological parameters and PSMA expression could not be demonstrated. Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.
Springer